The broader health-care sector faced downward pressure during the session, reflecting a wider market rotation. As traders reassessed their portfolios, the retreat from defensive holdings underscored a renewed appetite for tech-focused assets. For AstraZeneca and Ionis, the failure of Wainua in pivotal testing marks a significant hurdle for the drug's development timeline, drawing immediate negative reactions from shareholders tracking the company's experimental pipeline.
In section Market Quotes
AstraZeneca and Ionis Shares Slide Following Clinical Trial Setback
AstraZeneca and Ionis Pharmaceuticals saw their share prices plummet after their collaborative heart disease treatment, Wainua, failed to reach its primary efficacy endpoint in a late-stage clinical trial. The disappointing results arrived as investors shifted capital away from defensive health-care stocks and back into higher-growth technology equities.
Comments (0)
No comments yet. Be the first!